A study published in The New England Journal of Medicine in 2019 reported that among patients with BRCA1/2-mutated advanced breast cancer who received talazoparib, an FDA-approved PARP inhibitor, the objective response rate was 62.6% and the median progression-free survival was 8.6 months (Litton et al. 2018). This evidence concerns the gene BRCA1 and breast cancer.